<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">S. Imbert</style></author><author><style face="normal" font="default" size="100%">A. C. Normand</style></author><author><style face="normal" font="default" size="100%">D. Costa</style></author><author><style face="normal" font="default" size="100%">F. Gabriel</style></author><author><style face="normal" font="default" size="100%">L. Lachaud</style></author><author><style face="normal" font="default" size="100%">C. Schuttler</style></author><author><style face="normal" font="default" size="100%">S. Cassaing</style></author><author><style face="normal" font="default" size="100%">C. Mahinc</style></author><author><style face="normal" font="default" size="100%">L. Hasseine</style></author><author><style face="normal" font="default" size="100%">M. Demar</style></author><author><style face="normal" font="default" size="100%">S Brun</style></author><author><style face="normal" font="default" size="100%">C. Bonnal</style></author><author><style face="normal" font="default" size="100%">A. Moreno-Sabater</style></author><author><style face="normal" font="default" size="100%">Pierre Becker</style></author><author><style face="normal" font="default" size="100%">R. Piarroux</style></author><author><style face="normal" font="default" size="100%">A. Fekkar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Clinical Isolates from Aspergillus Section Circumdati</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antifungal susceptibility testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillus ochraceopetaliformis</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillus sclerotiorum</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillus section Circumdati</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillus westerdijkiae</style></keyword><keyword><style  face="normal" font="default" size="100%">azole resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">MALDI-TOF mass spectrometry</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jun-04-2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">67</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The clinical involvement and antifungal susceptibility of Aspergillus section Circumdati are poorly known. We analyzed 52 isolates, including 48 clinical isolates, belonging to 9 species inside the section Circumdati. The whole section exhibited, by the EUCAST reference method, a poor susceptibility to amphotericin B, but species/ series-specific patterns were observed for azole drugs. This underlines the interest in getting an accurate identification inside the section Circumdati to guide the choice of antifungal treatment in clinical practice.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>